Older age has been associated with worse outcomes in low-grade gliomas (LGGs). Given their rarity in the older population, determining optimal treatment plans and patient outcomes remains difficult. OBJECTIVE: To retrospectively study LGG survival outcomes in an older population stratified by molecular genetic profiles. METHODS: We included patients age ≥40 yr with pathologically confirmed World Health Organization grade II gliomas treated at a single institution between 1995 and 2015. We collected tumor genomic information when available. RESULTS: Median overall survival for the entire group (n = 111, median age 51 yr, range 40-77 yr) was 15.75 yr with 5-and 10-yr survival rates of 84.3% and 67.7%, respectively. On univariate analysis, patients with isocitrate dehydrogenase (IDH) mutation had significantly increased survival compared to IDH wildtype (hazard ratio [HR] 0.17 [0.07-0.45], P < .001). Older age, seizure at presentation, larger tumor size, IDH wildtype, biopsy only, chemotherapy, and radiation were significantly associated with shorter survival based on univariate analyses. In patients with known IDH status (n = 73), bivariate analysis of IDH mutation status and age showed only IDH status significantly influenced overall survival (HR 0.22 [0.07-0.68], P = .008). Greater surgical resection was predictive of survival, although extent of resection significantly correlated with IDH mutation status (odds ratio 7.5; P < .001). CONCLUSION: We show that genomic alterations in LGG patients ≥40 occur at high rates like the younger population and predict a similar survival advantage. Maximizing surgical resection may have survival benefit, although feasibility of resection is often linked to IDH status. Given the importance of molecular genetics, a redefinition of prognostic factors associated with these tumors is likely to emerge.
Prior to discovery and incorporation of these molecular and cytogenetic features, retrospective database studies and randomized controlled trials (RCTs) indicated that LGGs present more aggressively and have worse outcomes when they occur in patients older than 40. [8] [9] [10] [11] By analyzing some of these RCTs, a 2002 paper by Pignatti et al 12 established 5 criteria that indicate poor prognosis for patients with LGGs: age >40 yr, astrocytoma histology subtype, largest diameter of the tumor >6 cm, tumor crossing the midline, and presence of neurological deficit before surgery. While older age remains a risk factor, it has been difficult to study the true impact of age in LGGs because of the relative rarity of these tumors in older patients. As such, predicting outcome and determining optimal treatment plans of surgery, radiation, and chemotherapy remains a challenge. 13 Particularly, since prognostically favorable IDH mutations are more common in patients younger than 40 yr old, absence of molecular and genetic data in these past trials limits interpretation of whether patient outcomes are truly dependent on patient age or simply a worse genomic profile. 14, 15 In this study, we present outcomes from the largest reported single-institution population of patients with grade II glioma and high-risk criteria of age 40 yr or greater. Including IDH mutation and 1p19q codeletion status, we examined whether overall survival (OS) within an older population is influenced by molecular markers. 1, [8] [9] [10] [11] [12] [16] [17] [18] [19] 
METHODS

Patient Data Acquisition
We performed a retrospective review for all patients who received surgery for diagnosis and/or resection of a grade II glioma by World Health Organization (WHO) 2007 criteria who were ≥40 yr old at the time of diagnosis from January 1, 1995 to December 31, 2015 at a single institution. Neuropathologists determined tumor grade from operative specimens. Patients with histologic grade III gliomas, incomplete medical records, or who did not undergo surgery for brain tumor at the institution were excluded from this study. Institutional review board approval was obtained for the retrospective chart review. Of note, we did not obtain patient consent for this study since it was retrospective collection of data and many of the patients were deceased at time of data collection.
The following information was obtained: date of birth, gender, date of glioma diagnosis, date of first intracranial disease progression, date(s) of craniotomy, treatment with chemotherapy (yes/no), treatment with radiation therapy (yes/no), and neurosurgical and oncologic visit notes to determine seizure as presenting symptom and preoperative Karnofsky Performance (KPS) score.
We also retrospectively reviewed tumor pathology, including both histologic and genomic analysis, where possible, to avoid wrong diagnoses. Fluorescence in situ hybridization was used to detect deletion of chromosomes 1p and 19q. Tumors with deletions of only 1p or 19q were grouped with 1p19q non-codeleted tumors. Thirteen patients with tumors who were 1p19q codeleted but did not have IDH status information were grouped into the IDH-mutant category since virtually all 1p/19q codeleted oligodendrogliomas have a mutation in isocitrate dehydrogenase 1 (IDH1) at arginine 132 (R132) or the analogous residue arginine 172 in IDH2 (R172). 3, 20 In some cases, IDH1 mutation was detected using immunohistochemistry for cytoplasmic staining for R132H-mIDH1 and scored as positive by our institution's neuropathologists. For other cases, further genotyping was performed with SNaPshot genotyping of codon 132 of the IDH1 gene and codon 172 of the IDH2 gene. 18 Preoperative imaging was reviewed to determine presence of enhancement, tumor location, and maximum tumor size. Following surgery for diagnosis, some patients received radiotherapy and/or adjuvant chemotherapy. This treatment typically involved fractionated 3-D-conformal radiotherapy and temozolomide, or procarbazine, CCNU (lomustine), and vincristine chemotherapy (PCV).
The extent of surgical resection was determined by postoperative imaging. Operative reports were used in the case of planned biopsy-only cases. The definition of gross total resection (GTR) was no evidence of remaining T2/fluid-attenuated inversion recovery (FLAIR) hyperintensty not deemed to be edema in the region of previous abnormality after excision as judged by a neuroradiologist. There were no GTRs in cases where tumor demonstrated enhancement. Subtotal resection (STR) was defined as craniotomy procedure where tumor was debulked but there was residual disease noted by radiologists on postoperative imaging. If tissue was solely obtained for diagnosis without debulking, the procedure was classified as biopsy only. Progression of disease was determined by neuroradiologist interpretation of return or increase in T2/FLAIR hyperintensity not felt to be consistent with edema or treatment effect and/or development or increase of tumor enhancement pre-and postgadolinium contrast brain magnetic resonance imaging (MRI).
Data Analysis and Statistical Methods
The primary end point in this study was OS, calculated as the time from diagnosis to death. Additionally, the time to imaging progression, calculated as the time between the first surgery and worsened tumor burden on imaging, was evaluated as a secondary measure. Official death records, if not obtained in chart review, were obtained from the Social Security Death Index or by online obituary. At the time of the data analysis, 72 patients (64.9%) were known by recent clinical follow-up to be alive and were appropriately censored in the survival analysis. There were no patients lost to follow-up. If there was missing data, we did not include patients with missing data for that particular analysis. All genomic analyses were only performed for patients with data.
Survival analyses were performed using Kaplan-Meier product limit estimators and univariate and bivariate Cox proportional hazards models. For the bivariate analysis, we included age as a continuous variable and IDH mutation status as a binary variable, as these were central to our research question. Given the small number of deaths in the dataset, we chose not to include other variables in order to maximize power in the model. Treatment strategies were compared using chi-square analysis and by logistic regression. Differences in age between IDH populations were compared using t-test. Calculations were performed using SAS (version 9. 
RESULTS
Clinical Data
Among the total 111 cases, the mean age at time of diagnosis was 51.4 yr ( Molecular genomic data of tumor specimen were complete in 73 cases, allowing multivariate analysis in that cohort. The demographics for these 73 patients were similar to the total population (Table 1) . Sixty-five percent of patients were alive at the time the data for this study were compiled.
Outcome Analysis
Median OS for all 111 patients was 189 mo (15.75 yr) with 5-and 10-yr survival rates of 84.3% and 67.7%, respectively. By logrank comparison, there was no significant difference in survival based on histologic pathology, although oligodendroglioma and mixed glioma trended towards higher survival rates compared to patients with astrocytoma (P = .19). Median OS for patients with astrocytomas was 11.5 yr (138 mo), median OS for patients with oligodendrogliomas was 21 yr (252 mo), whereas median OS for patients with oligoastrocytomas had not yet been reached at time of data collection (Table 1) .
There were 39 cases of progression that led to a second surgery. Eleven of these cases progressed to grade III (28.2%) and 15 (38.5%) progressed to grade IV. Thirteen tumors remained grade II (33.3%). Median progression-free survival for the entire group was 8.2 yr.
Molecular Data
For patients with IDH mutations (n = 54), OS was significantly increased compared to patients without the mutation (n = 19). Five-year and 10-yr OSs were 94.2% and 85.8%, respectively, for IDH-mutant patients, and 67.4% and 36.8%, respectively, for IDH-wildtype patients (hazard ratio [HR] 0.175 [95% confidence interval 0.07-0.45], P < .001, Figure 1 ). Five-year and 10-yr progression-free survivals were 77.3% and 56.3%, respectively, for IDH-mutant patients and were 57.4% and 39.4%, respectively, for IDH-wildtype patients (HR 0.56 [0.28-1.15], P = .11). Of IDH-mutant cases, 44.4% progressed, whereas 57.9% progressed of IDH-wildtype cases (Table 2) . There was a trend towards older median age in the IDH-wildtype population (53.8 yr) compared to the IDH-mutant population (50.1 yr), although this was not significant (P = .07).
By univariate analysis, factors predicting worse OS included Table 3 ).
In a bivariate model with age and IDH status, IDH mutation was the only predictor of survival (HR 0.22 [0.07-0.68], P = .008; Table 4 ). Bivariate analysis of age and extent of resection showed that age and any surgical resection beyond biopsy predicted significantly improved survival (age HR Logistic regression analysis of extent of resection based on IDH mutation status showed there was significantly higher odds of getting a GTR in tumors that harbored IDH mutations. Conversely, there were significantly higher odds of biopsy in cases of IDH wildtype (OR 7.57, [95% confidence interval 2.59-24.85], P < .001; Table 5, Figure 2 ). Within the IDH-mutant population and those with known 1p19q status, 1p19q codeletion occurred in 75.5% of patients. Analysis of patients with 1p19q codeletion (37 patients) compared to 1p19q non-codeleted (12 patients) showed a significantly longer survival in the group with 1p19q codeletion (HR 0.172 [0.04-0.72]; P = .007; Figure 3 ).
DISCUSSION
This study represents the largest reported single-institution clinical outcomes of patients with grade II glioma and high-risk criteria of age 40 yr or greater in the postmolecular genomic era. In the management of LGGs, the "Pignatti criteria" have held that patients with age ≥40 yr have worse prognosis, along with patients with tumor size >6 cm, tumor crossing midline, neurological deficit at initial presentation, and astrocytoma histopathology. 12 Recently, however, molecular alterations of these tumors, such as IDH mutations and 1p and 19q codeletion, have been found in high numbers of diffuse gliomas, ∼80% to 90%, and significantly influence outcome (Table 6 ). 1 Although tumors harboring these mutations or genomic alterations typically present in the third or fourth decade of life, our study reports on the rarer population of older patients with LGG, and still finds a high IDH mutation rate of 74% and 1p19q codeletion rate of 75.5% in those with known genotype. Although univariate analysis showed older age was a significantly negative prognostic factor for survival, in the subgroup of patients with known IDH status, bivariate survival analysis examining IDH mutation and age determined that IDH-mutant status was prognostic of survival, while age was not. This finding suggests that molecular pathology of diffuse glioma may be more important than the age of the patient in determining clinical outcome. In the pre-molecular genomic era of the 1990s and 2000s, prognostic factors in LGGs were looked at extensively by both single-institution and multicenter RCTs. In their retrospective examination of prognostic factors of 379 patients with LGGs in 1997, Lote et al concluded that "prognosis in LGG following postoperative radiotherapy seemed largely determined by the inherent biology of the glioma and patient age at diagnosis." 16 In support of this, 20 yr later in 2017, Youland et al 21 reported worse outcomes in their elderly group of 55 yr and older, although they did not use any genomic criteria in their analysis of patient outcomes. 17 Under the scope of molecular genetics, however, recent studies suggest that the inherent tumor biology seems to trump more traditional prognostic factors, including age. In a 2014 study of patients of all ages with grade II and grade III gliomas, Sabha et al 22 demonstrated that molecular data from the tumors was the only significant predictor of patient progression-free and OS. IDH mutation status, 1p/19q codeletion, and PTEN deletion were predictive of over overall survival in a multivariate model, while none of the clinical or demographic factors such as age, tumor size, performance status, or tumor histology were found to be predictive. More recently, Hayashi et al 23 reported on 57 patients with 1p/19q codeleted gliomas and found that the only significant predictors of poor outcome were a gain of chromosome 19p and grade III histology. They found no significant difference in the OS of the patients with respect to age (≥40 vs <40 yr), degree of resection, maximum tumor diameter (≥5 vs <5 cm), histological subtype, and MGMT promoter methylation status. 27 Investigated the impact of surgical resection on survival after controlling for IDH1 status in malignant astrocytomas-128 patients with grade III anaplastic astrocytomas and 207 patients with grade IV glioblastoma. Median age of the IDH-mutant population was significantly younger (median age 37 yr) than the IDH-wildtype population (57 yr, P < 0.001). IDH1 mutations were identified in 86 of 128 AAs (67%) and 27 of 207 GBM (13%). Sabha et al 22 Analyzed outcomes of 108 patients with grade II and grade III nonenhancing gliomas. A total of 93 cases with IDH mutations were detected (86% of total cohort). Patient age was examined as >50 and ≤50, which, along with clinical variables (tumor diameter, extent of resection, performance status), and pathology (tumor type and grade), were not predictive of OS or PFR. IDH mutation status alone was predictive of longer OS and PFR for the entire group of tumors; 1p/19q deletion alone was predictive of OS but not PFR. Hartmann et al 1 Determined mutation types and frequencies in 10 010 diffuse gliomas. The average age of patients with gliomas of WHO grade II carrying IDH1 mutations was 41.3 yr while glioma patients without mutations averaged 42.8 yr (not significant). The mutation rate was 72.7% for grade II astrocytoma, 82.0% for grade II oligodendroglioma, and 81.6% for grade II oligoastrocytoma.
These results support our findings that traditional prognostic factors, such as age, may be less important in the setting of molecular markers. Older patients may not inherently have worse prognosis based on age, but rather, as our data suggest, due to a slightly lower chance of having an IDH mutation. Just as TERT promoter mutation frequency increases with patient age at diagnosis, it is possible that IDH mutation frequency decreases with patient age. 24 While our study did not show a significant difference in IDH mutation rate by age, it did occur at a lower rate than in studies of LGGs including younger ages (68% vs up to 82%-91%, Table 6 ). In 2013, Gorlia et al validated new prognostic models from the European Organisation for Research and Treatment of Cancer (EORTC) by studying patient outcomes from tumors that had undergone central pathologic review rather than by local pathologist. 25 Even more strikingly, in 2015 The Cancer Genome Atlas Research Network (TCGA) redefined glioma survival rates by molecular genomic classification rather than histologic classification. 3 Along these lines, future outcomes analyses from large RCTs that include the molecular genomic information of tumors may allow re-examination and evolution of LGG prognostic factors.
Extent of tumor resection is another common prognostic factor, with some large RCTs of gliomas, such as the EORTC 22844, finding significantly improved OS with increasing tumor resection rates. 26 Although extent of surgical resection was highly significant on univariate analysis in our study, our study was limited to only bivariate models due to the small sample size of patients with known IDH status and limited number of events (deaths) per variable (n = 73, 18 deaths). 27 Of these multiple bivariate analyses, the analysis of extent of resection and IDH status showed that both were significantly associated with survival. In logistic regression analysis, we found that IDHmutant status and extent of surgical resection were highly correlated, with IDH-mutant status predicting a 7.5 times increased odds of a GTR than STR. This may be due to IDH-mutant tumors occurring in greater frequency frontal and temporal lobes, which, especially when right sided, lend themselves to safer maximum extent of resection. These findings have been similarly highlighted by other recent series. Youland et al 21 found in that older patients with gliomas benefited from greater extent of resection, yet they did not have correlative mutation status of these patients. 17 In studies of higher grade gliomas, Beiko et al 28 were the first group to report on IDH1 mutation as an independent predictor of complete resection of enhancing disease, with 93% complete resections among mutants vs 67% among wildtype (P < .001). They further suggested that, given the decrease in IDH mutation after age 40, factoring in the clinical feature of age into risk stratification was an "incomplete surrogacy" for IDH status. 28 Among grade III gliomas, Kawaguchi et al 29 found that, while all patients undergoing GTR had longer median survival and progression-free survival times compared to those of non-GTR patients, the benefits of GTR was highest for the group with the IDH mutation without a 1p19q codeletion. The IDH mutant, 1p19q codeleted tumors, and the IDH-wildtype tumors did not show survival difference based on GTR vs non-GTR. In a study of 151 grade II gliomas, Leeper et al 30 found no statistically significant difference in extent of resection achieved between any of the TCGA-defined molecular subgroups; however, only 9% of their population was IDH wildtype. While our study was not powered for this subgroup analysis, the role of resection and change in tumor volume with surgery based on molecular diagnosis is an important area of future research, with efforts already underway to allow for intraoperative determination of IDH status. 31 Our paper did not find that adjuvant chemotherapy or radiation offered significant survival benefit, which differs from several recent phase II and phase III studies. [32] [33] [34] This may be because our study looks at patients who already have at least 1 high-risk criteria and, therefore, our population, as a whole, may have tended to receive more aggressive treatment at baseline. Only 18.9% of our population was observed rather than receiving some form of postoperative chemotherapy or radiation. Similarly, in a study of 94 patients with LGG who were 55 yr and older treated at Mayo Clinic, Youland et al 19, 21 also found extent of surgical resection to be the only treatment intervention to significantly affect outcome. Neither radiation alone, chemotherapy alone, or combined chemoradiation had a survival impact, and their rate of postoperative observation was slightly higher than ours at 21%. 19, 21 To date, there have already been 2 phase III chemoradiation trials looking at treatment outcomes of LGG according to molecular diagnosis, and these include age ≥40 as a highrisk factor. In the EORTC 22033-26033, study of temozolomide chemotherapy vs radiotherapy in high-risk patients with LGG, subgroup analysis determined that IDH mutant, non-codeleted tumors had longer progression-free survival with radiation alone compared to temozolomide alone. 32 However, patients with IDH mutant, 1p19q codeleted tumors or IDH-wildtype tumors showed no treatment-related difference in progressionfree survival. Additionally, Buckner et al 34 reported on highrisk patient outcomes after randomization to radiation alone vs PCV and radiation and found that patients with IDHmutant tumors had significantly improved progression-free and overall survival compared to the IDH-wildtype cohort. More impressively, the IDH-mutant cohort treated with PCV and radiation had significantly improved survival over the IDHmutant cohort treated with radiation alone. On their multivariate analysis for OS, age <40 was one of the significant factors indicating improved OS, while IDH-mutant status was not. Other positive prognostic factors included combined radiation and chemotherapy treatment and oligodenroglioma histology. These same variables were also found to significant influence improved progression-free survival, with the inclusion of IDH mutation status as an additional significant factor. Thus, while age still bore out to be influential in survival, similar to our findings, IDH mutation status predicted better survival than IDHwildtype patients and had a significant influence on outcomes. Looking forward, these randomized trials will be very powerful for defining the role of molecular diagnosis.
Study Limitations
There are many inherent limitations of our study given its retrospective, chart-review design. Treatments were determined based on a variety of factors, including patient risk factors, patient or physician preference, and time period in which the patient was treated. Given the body of literature of the 1990s and 2000s that supported older age as a risk factor for worse outcomes, it is likely that our patients were treated more aggressively. In this population, adjuvant treatment of radiation and chemotherapy were not assigned randomly but chosen by clinicians based on perceived risk. Therefore, our results of worse outcome associated with adjuvant treatment more likely indicates that patients deemed more high risk for worse outcome were more likely to receive this therapy.
The findings of our study were also diminished by the fact that we used the 2007 WHO classification of gliomas rather than the 2017 WHO grading scheme, mainly because most of our patients were diagnosed and treated based on 2007 classification. This renders survival based on histopathology less meaningful, as oligoastrocytoma no longer exists. Future analysis of molecular diagnosis and treatment outcomes across all ages is warranted, especially given recent findings from larger phase III trials with molecular genomic data showing that age <40 still has positive prognostic implications. Additionally, surgical treatment perhaps varied by surgeon and this could influence rates of resection. Furthermore, the extent of resection data based on MRI analysis was simplified into three tiers, and the size of tumors was recorded based on largest in a single dimension. We did not account for volume of T2/FLAIR hyperintense tumor or enhancing tumor, both pre-and postoperatively, which would be more sensitive and accurate to account for residual tumor burden and extent of resection. While we did look at Pignatti criteria data for this study, we limited ourselves to KPS as proxy for neurological deficit and only had two patients with tumor crossing midline so excluded these data from analysis. While size of tumor and seizure at diagnosis were significant on univariate analysis, we did not include this in our final models due to previously discussed limitations of our multivariate survival analyses. Astrocytic pathology trended towards predicting a worse survival, but not significantly so.
As for molecular data, we were limited to only 73 of our 111 patients, limiting the robustness of our survival analyses since there were only 18 deaths in this population. We also did not capture large enough numbers of other molecular and genomic alterations to account for their influence in this study, such as p53 mutation, PTEN mutation, and TERT mutation. We did not have the age group of <40 for outcomes comparison, which is a significant limitation to this paper and can be reported on in upcoming analyses from our group.
CONCLUSION
The present study shows that IDH mutation and 1p19q chromosomal codeletion of LGG in patients ≥40 occurs at high rates like the younger population and predicts a similar survival advantage, and this should be considered when determining optimal management strategy in this population. Tumors harboring IDH mutations are known to present in more surgically accessible areas, and, as found in this study and many previous, maximizing extent of resection seems to hold a withstanding influence on improved survival. Prior analyses indicating older age as a poor prognostic indicator could have associated with IDH mutations occurring at slightly lower frequency in this population. Given that current and future studies include the molecular genetics of gliomas, it is likely time that the 15-yr-old 5 clinical "Pignatti criteria" give way to redefined prognostic factors that reflect the molecular era and, as such, more accurately predict outcome and treatment response.
Disclosure
M
aximal safe surgical resection of a presumed supratentorial diffuse low-grade glioma (LGG) is considered standard of care.
1 This provides tumor tissue for histological and genetic analysis, reduces tumor burden and subsequent risk of tumor progression, and may reduce seizures associated with the tumor -it may also be associated with improved survival. 1 Recent reports of the beneficial effect of postoperative radiation and chemotherapy in select patients were largely based on criteria proposed by Pignatti et al 2 more than a decade ago. 3,4 They proposed 5 criteria that portended a worse prognosis for adult patients with a supratentorial LGG; age type = "Other" >40 years, astrocytoma histology, tumor diameter >6 cm, tumors crossing the midline, and the presence of a neurological deficit before surgery. 2 A critical factor was age; 40 years was considered the bellwether point for prognostication and treatment decision-making. [2] [3] [4] The dawn of the new era of molecular medicine changed our philosophy on the management of LGG. In 2016, the World Health Organization (WHO) reclassified neuroepithelial tumors based on molecular markers such as 1p/19q and isocitrate dehydrogenase (IDH) mutations. 5 Currently, these markers supercede histological criteria for tumors such as an oligodendroglioma and some categories such as oligoastrocytomas have been altogether culled. 5 Overall, it has had a constructive effect on our understanding of gliomas. Management of these histologically and genetically diverse tumors is now predicated by the tumor molecular profile and henceforth, it is inconceivable that any clinical trial will be undertaken without consideration of these biomarkers.
The p53 mutation (for astrocytomas) and 1p/19q deletion (for oligodendrogliomas) are pathognomic and mutually exclusive. 5 A recent addition to this select list was isocitrate dehydrogenase (IDH) mutations. 6 IDH mutations are reported in hematological malignancies such as acute myeloid leukemia but among solid tumors, they are particularly unique to gliomas. IDH mutations may occur as both IDH 1 and IDH 2 mutations. IDH 1 mutations appear to be more relevant and may be detected by standard immunohistochemical studies that are ubiquitously available -on the other hand, detection of IDH 2 mutations requires genomic sequencing studies. Both IDH mutations tend to occur early in glioma development and may be seen with either p53 mutations or 1p/19q deletions. They contribute to glioma progression through induction of the HIF-1 pathway and genome-wide histone and DNA methylation alterations through the oncometabolite 2-hydroxyglutarate. 1, 6, 7 IDH mutations also alter the glioma microenvironment by affecting collagen maturation and impairing basement membrane function. 7 They may predispose a patient to seizures or portend worse postoperative seizure occurrence. IDH 1 mutations are commonly seen in LGG and secondary glioblastoma (GBM) but rarely ever in primary GBM or malignant gliomas with EGFR amplification. 7 They frequently accompany MGMT promoter hypermethylation and correlate with the Ki-67 labeling index. 8, 9 They are, hence, a major marker for OS in LGG and malignant gliomas -and are possibly more powerful than the Pignatti score in their predictive capacity. 8, 9 This study goes back to the tipping point effect of age viewed in light of this new molecular information. In LGG patients >40 years of age with IDH 1 mutations, the authors report improved survival; the presence of a 1p/19q deletion had a similar beneficial effect. Also, greater surgical resection was predictive of survival -and extent of resection significantly correlated with IDH mutation status. Their findings confirm previous reports of the salutary effect of IDH1 mutations in gliomas and the value of maximal safe surgical resection. It proves the need to use molecular markers to determine the optimal management of a LGG, regardless of age. It may be that age is a secondary factor, simply reflecting the frequency of occurrence of these changes. In other words, younger patients tend to have better outcomes because they have IDH 1 mutated tumors more frequently. Older patients who have the same molecular changes may fare the same.
The characterization of genetic findings such as IDH mutations, p53 mutations, and 1p/19q deletions has revolutionized our understanding of diffuse LGG. It has led to a more precise pathological classification, the potential for better therapies, and improved prognostication. But this may simply be the proverbial "tip of the iceberg"-in addition to prognostication, there may be therapeutic benefits. In acute myeloid leukemia, IDH inhibition appears to the clinically effective -possibly by allowing malignant blasts cells to differentiate and become post mitotic. There may be similar value in the future with IDH inhibitors for gliomas. IDH1-R132H mutations are reportedly associated with a more severe phenotype of postoperative epilepsy -this suggests potential for an antiepileptic therapeutic effect of an IDH 1 inhibitor. 10 This is a nice study that improves our understanding of the impact of genomic alterations on the clinical trajectory of a glioma in older patients. It provides clinicians useful information when counseling these patients. Such findings may alter our management of these patients significantly, causing us to look anew at older criteria used to determine patients who are at higher risk for tumor progression. The use of radiation and chemotherapy is not without side effects -molecular genomic information may lead to a more abstemious use of these modalities or at least a more targeted individualized approach.
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